Patient Information Leaflet Translation: UK and EU Regulatory Requirements

Key Takeaways

• Every medicinal product sold in the EU must include a Patient Information Leaflet (PIL) in the official language of each member state where it is marketed — this is a legal requirement, not a recommendation.
• In the UK, MHRA requirements apply separately following Brexit, with the PIL now referred to as the Package Leaflet in UK submissions.
• PIL translations must follow the EMA’s QRD template and EU readability guidelines, which require user testing in the target language population.
• A PIL that fails language compliance can delay marketing authorisation, trigger product recalls, or result in regulatory action.
• Specialist pharmaceutical translators — not general medical translators — are required for PIL work.

Patient Information Leaflet (PIL) translation sits at the intersection of pharmaceutical regulation, plain language requirements, and multilingual compliance. For any company marketing a medicinal product in the EU or UK, understanding these requirements is not optional — it is part of the marketing authorisation process.

This article covers what the regulations require, where the UK and EU frameworks differ post-Brexit, and what a compliant PIL translation process looks like in practice.

What Is a Patient Information Leaflet?

A Patient Information Leaflet is the document included inside the packaging of a medicinal product. It is written for patients and carers, not healthcare professionals, and provides essential information on:

• What the medicine is and what it is used for
• Contraindications and precautions
• How to take the medicine, including dosage
• Possible side effects
• Storage instructions
• Product composition

In the EU regulatory framework, the PIL is Annex III of the marketing authorisation dossier. The Summary of Product Characteristics (SmPC) is Annex I, written for healthcare professionals. Both require translation into the official language of each member state where the product is sold, but the PIL and SmPC are distinct documents with different audiences, reading levels, and translation requirements.

EU Regulatory Requirements for PIL Translation

The Legal Basis

Under Directive 2001/83/EC (as amended), all medicinal products authorised for the EU market must include labelling and a package leaflet in the official language or languages of each member state where they are placed on the market. This applies whether authorisation is obtained via the centralised procedure (through the EMA) or national procedures.

For products authorised via the EMA’s centralised procedure, the EMA issues the approved SmPC and PIL in all 24 official EU languages. For national authorisations, the marketing authorisation holder is responsible for providing compliant translations in the relevant national language(s).

The QRD Template

The EMA’s Quality Review of Documents (QRD) working group maintains standard templates for the PIL and SmPC. These templates specify the structure, section headings, and approved wording for standard phrases — and translations must follow these templates exactly.

Deviating from QRD template wording, even to improve readability, requires regulatory justification. Translators working on PILs must be familiar with the current QRD template for the target language, as approved wording varies by member state.

Readability Requirements

The EU Readability Guideline (2009) requires that PILs be tested for readability and comprehensibility with lay users in the target language population. The guideline specifies a user consultation process in which representative members of the target patient population read the leaflet and answer questions about it — demonstrating that the content is understandable.

This requirement applies to the translated PIL, not just the original. A direct, technically accurate translation of an English PIL may still fail readability testing if the translated language does not communicate clearly to patients in the target country. This is why PIL translation requires more than terminological accuracy — it requires cultural and linguistic adaptation within the constraints of the QRD template.

UK Requirements Post-Brexit

Since the UK left the EU’s regulatory framework, the MHRA operates independently of the EMA. For products authorised in Great Britain (England, Scotland, Wales), the MHRA applies its own requirements under the Human Medicines Regulations 2012 (as amended).

Key differences from the EU framework:

Separate authorisation — a product with EU marketing authorisation does not automatically have UK authorisation. Companies must apply to the MHRA separately (unless relying on the MHRA’s international recognition procedure).

UK-specific PIL — the PIL for the UK market is now referred to as the Package Leaflet in MHRA guidance and must reflect UK-specific prescribing information, product licence numbers, and regulatory text. The EU-approved PIL cannot simply be reused for UK submissions without review.

Northern Ireland — Northern Ireland remains aligned with EU pharmaceutical regulation under the Windsor Framework, meaning EU-approved PILs apply for products placed on the Northern Ireland market. This creates a situation where a single company may need three separate PIL versions: EU (24 languages), Great Britain (English), and potentially a bilingual version for Northern Ireland.

MHRA QRD template — the MHRA maintains its own QRD templates for UK PILs. These differ from the EMA templates, particularly around standard phrases relating to regulatory bodies, pharmacovigilance reporting, and product licence wording.

What a Compliant PIL Translation Process Looks Like

Step 1: Source document review

Before translation begins, the source PIL should be reviewed against the current approved SmPC. Inconsistencies between the SmPC and PIL in the source language will propagate into every translated version and create regulatory problems downstream.

Step 2: QRD template alignment

The translator must work with the current QRD template for the target language. Standard phrases must use the approved wording, not a fresh translation of the English equivalent. This requires access to current EMA or MHRA QRD materials.

Step 3: Translation by a pharmaceutical specialist

PIL translation requires a translator with pharmaceutical or clinical background, not a general medical translator. The translator must understand the regulatory context, the SmPC on which the PIL is based, and the approved terminology in the target language.

Step 4: Independent review

ISO 17100:2015 requires an independent review by a second qualified translator. For PILs, this review should specifically check QRD template compliance, terminology against the approved SmPC, and consistency of safety-critical language such as contraindications and dosage instructions.

Step 5: Readability consideration

For new marketing authorisations or significant variations, the translated PIL may need to undergo user testing in the target language. This is a regulatory requirement under the EU Readability Guideline and is separate from the translation quality review.

Step 6: Certification

The completed translation should be accompanied by a Certificate of Accuracy confirming it was produced by a qualified professional and reviewed independently. This forms part of the regulatory dossier.

Common Mistakes in PIL Translation

Using a general medical translator — PIL translation requires pharmaceutical expertise and familiarity with QRD templates. A translator skilled in clinical trial documents or medical device IFUs may not have the specific knowledge required for PIL work.

Translating standard phrases rather than using approved wording — QRD templates contain approved translations of standard phrases in each EU language. Retranslating these from English, even accurately, will result in a non-compliant PIL.

Ignoring the SmPC — the PIL must be consistent with the approved SmPC. Translators who work only from the PIL without reference to the SmPC risk introducing inconsistencies that regulators will identify during review.

Treating the EU and UK PILs as the same document — post-Brexit, these are separate documents with different regulatory requirements, different QRD templates, and potentially different approved content. Using one as a direct copy of the other creates compliance risk.

Summary

PIL translation is one of the most tightly regulated areas of pharmaceutical translation. The combination of QRD template requirements, EU readability obligations, post-Brexit UK divergence, and the direct patient safety implications of errors means this work requires specialists with deep regulatory knowledge — not just language skills.

Global LTS provides certified medical translation services for pharmaceutical companies and clinical research organisations, including PIL and SmPC translation across all EU official languages and for UK MHRA submissions. Contact us to discuss your project requirements.